US2012108555A1PendingUtilityA1

Mixtures or Organic Compounds for the Treatment of Airway Diseases

Assignee: CUENOUD BERNARDPriority: Dec 4, 2000Filed: Jan 9, 2012Published: May 3, 2012
Est. expiryDec 4, 2020(expired)· nominal 20-yr term from priority
A61P 43/00A61P 29/00A61P 11/00A61P 11/16A61P 11/08A61P 11/06A61K 31/4704A61K 31/575A61K 31/573A61K 31/57A61K 31/00
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A medicament comprising, separately or together, (A) a compound of formula (I) in free or pharmaceutically acceptable salt or solvate form and (B) a corticosteroid, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease, the molar ratio of (A) to (B) being from 100:1 to 1:300.

Claims

exact text as granted — not AI-modified
1 .- 15 . (canceled) 
     
     
         16 . A method for the treatment of asthma which comprises administering by inhalation to a subject in need of such treatment a pharmaceutical composition comprising effective amounts of
 (a) a compound of formula (I)   
       
         
           
           
               
               
           
         
         in free or pharmaceutically acceptable salt or solvate form; 
         (b) mometasone furoate; 
         and a pharmaceutically acceptable carrier, 
         wherein the molar ratio of (a) to (b) is from 5:1 to 1:10. 
       
     
     
         17 . A method according to  claim 16  wherein the pharmaceutical composition is a dry powder. 
     
     
         18 . A method according to  claim 17  wherein the average particle diameter of the dry powder is up to 10 μm. 
     
     
         19 . A method according to  claim 18  wherein the average particle diameter of 1 to 5 μm. 
     
     
         20 . A method according to  claim 16  wherein the pharmaceutically acceptable carrier is lactose monohydrate that has a particle diameter below 212 μm. 
     
     
         21 . A method according to  claim 16  wherein the molar ratio of (a) to (b) is from 3:1 to 1:7. 
     
     
         22 . A method according to  claim 16  wherein the molar ratio of (a) to (b) is from 2:1 to 1:2. 
     
     
         23 . A method according to  claim 16  wherein (a) is 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one maleate.

Join the waitlist — get patent alerts

Track US2012108555A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.